药明巨诺向股东Juno授予技术许可 总代价不超千万美元

财中社
15 May

5月15日,药明巨诺(02126)发布公告,宣布与主要股东Juno签订了一项许可协议。根据该协议,药明巨诺将向Juno授予其开发和商业化细胞治疗产品所需的JW sLVV生产工艺及相关技术知识的非独家许可。该协议的代价总额不超过1000万美元,包括不可退还的预付款和额外付款。截至最后可行日期,Juno直接持有药明巨诺约16.87%的股份,因而被视为公司的关联人士。协议规定,Juno将在许可协议生效后...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10